Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.

21 Apr 2022

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Death rates from ovarian cancer are predicted to fall by 17% in the UK and by 7% in EU countries in 2022 compared to 2017, according to new research published in the leading cancer journal Annals of Oncology today (Wednesday).

27 Jan 2022

Independent drug action responsible for greater clinical efficacy of combination cancer therapies

Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis.

19 Jan 2022

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

5 Jan 2022

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

14 Jul 2021

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020.

6 Feb 2021

New combination treatment for recurrent ovarian cancer shows positive outcomes

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

19 Nov 2020

Age can affect response to adjuvant treatment among patients with resected melanoma

Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not

23 Oct 2020

Common medication used to treat diabetic macular edema is less effective in Black patients

A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.

22 Oct 2020

SARS-CoV-2 spike protein may induce analgesia

A recent study published in the journal Pain in October 2020 adds another piece to the puzzle, showing that the virus is capable of dulling pain pathways. This may contribute to its early and extensive spread.

7 Oct 2020

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

30 May 2020

COVID-19 clinical trials show positive early results, says GlobalData

With the number of COVID-19 cases and deaths increasing with each passing day, the need for a therapeutic or a vaccine for the pandemic intensifies.

18 May 2020

New treatment improves survival for people with common liver cancer

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

13 May 2020

A faster and easier treatment option to prevent blindness in preterm infants

Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently.

23 Apr 2020

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

In the 2020 February 25 issue of Scientific Reports, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that levels of a circulating soluble immune checkpoint protein can be used as a potential marker to predict overall survival in patients with advanced HCC.

9 Mar 2020

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

8 Jan 2020

Maintenance chemotherapy after initial treatment more beneficial for metastatic colorectal cancer patients

A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment.

19 Dec 2019

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma compared to standard of care, showed results from a phase 3 study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

NCCN ORP plans to support phase II randomized trial for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.

28 Oct 2019